JP Yim, Getty Images
Industryweek 11031 051916elizabethholmesjpyim

Theranos Corrects Tens of Thousands of Blood-Testing Results

May 19, 2016
The tech company told federal health regulators at the Centers for Medicare and Medicaid Services that it had voided results from 2014 and 2015 generated by its testing devices, another devastating blow.

Blood-testing startup Theranos Inc. said it sent doctors and patients tens of thousands of corrected test results and voided two years of data from its devices, a devastating blow for the company that has come under scrutiny over the accuracy of its technology.

The Silicon Valley startup told federal health regulators at the Centers for Medicare and Medicaid Services that it had voided results from 2014 and 2015 generated by its testing devices, the Wall Street Journal reported. Theranos spokeswoman Brooke Buchanan confirmed the report by e-mail.

“Excellence in quality and patient safety is our top priority and we’ve taken comprehensive corrective measures to address the issues CMS raised in their observations,” Buchanan said in an e-mail. “As these matters are currently under review, we have no further comment at this time.”

Lauren Shaham, a spokeswoman for CMS, declined to comment.

Theranos is developing a technology that, the company has said, can run scores of diagnostic tests using only a few drops of blood. The Palo Alto, California-based startup has faced questions about whether its technology works and has been subject to investigations by the U.S. Securities and Exchange Commission, the U.S. Attorney’s Office in San Francisco, and federal and state health regulators. 

President and COO Sunny Balwani left the company last week, saying he was retiring. At the same time, Theranos reconfigured its board, adding former Amgen Inc. executive Fabrizio Bonanni.

Theranos’s business has grown mainly through its partnership with Walgreens Boots Alliance Inc., with about 40 of its testing centers placed in Walgreens outlets in Arizona. Walgreens spokesman Michael Polzin declined to comment on whether the drugstore chain would continue working with Theranos.

By Caroline Chen

Popular Sponsored Recommendations

You Cannot Stay Competitive by Bolting New Technologies to a Legacy ERP

Oct. 20, 2023
Read this white paper to understand the benefits of shifting to a next-generation ERP system as part of a DOP.

The Executive Guide to Best Practices for Ecommerce Integration

Oct. 2, 2023
Get ready to elevate your post-checkout experiences and thrive in today's unpredictable market. Learn why integration and automation are crucial to run operations more smoothly...

Simulation can accelerate the ROI of digital transformation - Ebook

July 12, 2023
Using simulation in conjunction with your design software can help your business reach its productivity goals.

Gain a competitive edge with real-world lessons on private 5G networks

Nov. 16, 2023
The use of private networks in manufacturing applications is rapidly growing. In this paper, we present valuable insights and lessons learned from the field with the goal of enhancing...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!